Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLS-012 +/- zimberelimab in advanced solid tumors
NCT05909436Phase 2Recruiting
- Sponsor
- Guangzhou Gloria Biosciences Co., Ltd.
- Start
- Oct 2022
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of brivestobart in solid tumor (2 arms), sponsored by Guangzhou Gloria Biosciences Co., Ltd. Primary endpoints: Dose-Limiting Toxicity and Maximum Tolerated Dose at 21 days and Treatment-Emergent Adverse Events at 24 months. Started Oct 2022; status: recruiting.
02
Drugs
brivestobart
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05909436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05909436.